Claims for Patent: 6,426,075

Summary for Patent: 6,426,075

Title:	Protease-activatable pseudomonas exotoxin A-like proproteins
Abstract:	This invention provides protease-activatable Pseudomonas exotoxin A-like (\"PE-like\") proproteins. The proproteins comprise (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a modified PE translocation domain comprising an amino acid sequence sufficiently homologous to domain II of PE to effect translocation to a cell cytosol upon proteolytic cleavage, wherein the translocation domain comprises a cysteine-cysteine loop that comprises a protease activatable sequence cleavable by a protease and wherein the cysteine-cysteine loop is substantially un-activatable by furin; (3) optionally, a PE Ib-like domain comprising an amino acid sequence up to 1500 amino acids; (4) a cytotoxicity domain comprising an amino acid sequence substantially homologous to domain III of PE, the cytotoxicity domain having ADP-ribosylating activity; and (5) an endoplasmic reticulum (\"ER\") retention sequence. The invention also provides methods of using these proproteins for killing target cells.
Inventor(s):	Fitzgerald; David J. (Rockville, MD), Reiter; Yoram (Ness Ziona, IL), Pastan; Ira (Potomac, MD)
Assignee:	The United States of America as represented by the Secretary of the (N/A) (Washington, DC)
Application Number:	09/297,851
Patent Claims:	1. A protease-activatable Pseudomonas exotoxin A-like ("PE-like") proprotein comprising: (a) a cell recognition domain that binds to an exterior surface of a targeted cell; (b) a modified PE translocation domain comprising an amino acid sequence with 80% or greater sequence identity to amino acids 280 to 344 of SEQ ID NO:2 and which effects translocation to a cell cytosol upon proteolytic cleavage, wherein the translocation domain comprises a cysteine-cysteine loop that comprises a protease activatable sequence cleavable by a protease and wherein the protease activatable sequence is refractory to cleavage by furin when incubated with furin at a 1:10 enzyme:substrate molar ratio at 25.degree. C. for 16 hour; (c) a cytotoxicity domain comprising an amino acid sequence with 80% or greater sequence identity to amino acids 400 to 613 of SEQ ID NO:2, the cytotoxicity domain having ADP-ribosylating activity; and (d) an endoplasmic reticulum ("ER") retention sequence. 2. The PE-like proprotein of claim 1 wherein the modified PE translocation domain has a PE domain II sequence (amino acids 253-364 of SEQ ID NO:1) modified with amino acids substitutions introducing the protease activatable sequence so as to cause cleavage by the protease between amino acids 279 and 280. 3. The PE-like proprotein of claim 1 wherein the protease activatable sequence is cleavable by a protease secreted by a cancer cell. 4. The PE-like proprotein of claim 1 wherein the cell recognition domain comprises an antibody that specifically binds to a cancer cell surface marker. 5. The PE-like proprotein of claim 2 wherein the protease activatable sequence is cleavable by prostate specific antigen ("PSA"). 6. The PE-like proprotein of claim 2 wherein the protease activatable sequence is cleavable by urokinase. 7. The PE-like proprotein of claim 2 wherein the protease activatable sequence is cleavable by neutral endoprotease, stromelysin, collagenase, cathepsin B, or cathepsin D. 8. The PE-like proprotein of claim 2 further comprising a PE Ib domain, and wherein said PE Ib domain, the cytotoxicity domain, and the ER retention sequence together have the sequence of domains Ib and III of native PE. 9. The PE-like proprotein of claim 3 wherein the cell recognition domain is coupled to the modified translocation domain through a peptide bond. 10. The PE-like proprotein of claim 5 wherein the protease activatable sequence is SKGSFSIQYTYHV (SEQ ID NO:11), HLGGSQQLLHNKQ (SEQ ID NO:12), or SKGKGTSSQYSNTE (SEQ ID NO:13). 11. The PE-like proprotein of claim 6 wherein the protease activatable sequence is DRVYIHPF (SEQ ID NO:3), VVCGERGFFYTP (SEQ ID NO:4), FFYTPKA (SEQ ID NO:5), KRRPVKVYP (SEQ ID NO:6), PVGKKRRPVKVY (SEQ ID NO:7), KPVGKKRRPVKV (SEQ ID NO:8), GKPVGKKRRPVK (SEQ ID NO:9), or TFAGNAVRRSVGQ (SEQ ID NO:10). 12. The PE-like proprotein of claim 8 wherein the cell recognition domain is an antibody coupled to the modified translocation domain through a peptide bond and wherein the antibody specifically binds a cancer cell surface marker. 13. A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a protease-specific Pseudomonas exotoxin A-like ("PE-like") proprotein comprising: (a) a cell recognition domain that binds to an exterior surface of a targeted cell; (b) a modified PE translocation domain comprising an amino acid sequence with 80% or greater sequence identity to amino acids 280 to 344 of SEQ ID NO:2 and which effects translocation to a cell cytosol upon proteolytic cleavage, wherein the translocation domain comprises a cysteine-cysteine loop that comprises a protease activatable sequence cleavable by a protease and wherein the protease activatable sequence is substantially un-activatable by fibrin when incubated with furin at a 1:10 enzyme:substrate molar ratio at 25.degree. C. for 16 hours; (c) a cytotoxicity domain comprising an amino acid sequence with 80% or greater sequence identity to amino acids 400 to 613 of SEQ WD NO:2, the cytotoxicity domain having ADP-ribosylating activity; and (d) an endoplasmic reticulum ("ER") retention sequence. 14. The composition of claim 13, further comprising a PE Ib-like domain, wherein: (a) the cell recognition domain is an antibody coupled to the modified PE translocation domain through a peptide bond and wherein the antibody specifically binds a cancer cell surface marker; (b) the modified PE translocation domain has a PE domain II sequence (amino acids 253-364 of SEQ ID NO:1) modified with amino acids substitutions introducing the protease activatable sequence so as to cause cleavage by the protease between amino acids 279 and 280; and (c) the PE Ib-like domain, the cytotoxicity domain and the ER retention sequence together have the sequence of domains Ib and III of native PE. 15. The composition of claim 14 wherein the protease activatable sequence is cleavable by prostate specific antigen or urokinase. 16. A method for killing a cancer cell comprising contacting the cell with a protease-specific Pseudomonas exotoxin A-like ("PE-like") proprotein comprising: (a) a cell recognition domain that binds to an exterior surface of a targeted cell; (b) a modified PE translocation domain comprising an amino acid sequence with 80% or greater sequence identity to amino acids 280 to 344 of SEQ ID NO:2 and which effects translocation to a cell cytosol upon proteolytic cleavage, wherein the translocation domain comprises a cysteine-cysteine loop that comprises a protease activatable sequence cleavable by a protease and wherein the protease activatable sequence cysteine-cysteine loop is substantially un-activatable by furin when incubated with furin at a 1:10 enzyme:substrate molar ratio at 25.degree. C. for 16 hours; (c) a cytotoxicity domain comprising an amino acid sequence with 80% or greater sequence identity to amino acids 400 to 613 of SEQ ID NO:2, the cytotoxicity domain having ADP-ribosylating activity; and (d) an endoplasmic reticulum ("ER") retention sequence. 17. The method of claim 16 wherein the cancer cell is a prostate cancer cell. 18. The method of claim 16 wherein the cancer cell is a colon cancer cell. 19. The method of claim 16 used in the treatment of a subject suffering from cancer.

Details for Patent 6,426,075

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2016-11-06
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2016-11-06